Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.

IF 8.2 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2024-11-01 DOI:10.3324/haematol.2023.284786

Charles Herbaux, Caroline Bret, Emmanuel Bachy, Pierre Bories, Roberta Di Blasi, Alexis Cuffel, Thomas Gastinne, Thierry Lamy, Mikael Roussel, Krimo Bouabdallah, David Beauvais, Guillaume Cartron, Jacques-Olivier Bay, Didier Blaise, Marie-Therese Rubio, Mohamad Mohty, Fabien Le Bras, Olivier Casasnovas, Julien Guy, Stephanie Guidez, Cristina Castilla Llorente, Olivier Hermine, Laurianne Drieu La Rochelle, Sylvain Carras, Blandine Guffroy, Sophie Caillat-Zucman, Roch Houot, Steven Le Gouill

引用次数: 0

查看原文本刊更多论文

Brexucabtagene autoleucel治疗复发性或难治性套细胞淋巴瘤，DESCAR-T注册中的意向治疗用药。

不详。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.